OBJECTIVE: The objective was to assess the cardiac effects of growth hormone (GH) therapy. Anthracycline-treated childhood cancer survivors frequently have reduced left ventricular (LV) wall thickness and contractility, and GH therapy may affect these factors. METHODS: We examined serial cardiac findings for 34 anthracycline-treated childhood cancer survivors with several years of GH therapy and baseline cardiac z scores similar to those of a comparison group (86 similar cancer survivors without GH therapy). RESULTS: LV contractility was decreased among GH-treated patients before, during, and after GH therapy (-1.08 SD below the age-adjusted population mean before therapy and -1.88 SD 4 years after therapy ceased, with each value depressed below normal). Contractility was higher in the control group than in the GH-treated group, with this difference being nearly significant. The GH-treated children had thinner LV walls before GH therapy (-1.38 SD). Wall thickness increased during GH therapy (from -1.38 SD to -1.09 SD after 3 years of GH therapy), but the effect was lost shortly after GH therapy ended and thickness diminished over time (-1.50 SD at 1 year after therapy and -1.96 SD at 4 years). During GH therapy, the wall thickness for the GH-treated group was greater than that for the control group; however, by 4 years after therapy, there was no difference between the GH-treated group and the control group. CONCLUSIONS: GH therapy among anthracycline-treated survivors of childhood cancer increased LV wall thickness, but the effect was lost after therapy was discontinued. The therapy did not affect the progressive LV dysfunction.
OBJECTIVE: The objective was to assess the cardiac effects of growth hormone (GH) therapy. Anthracycline-treated childhood cancer survivors frequently have reduced left ventricular (LV) wall thickness and contractility, and GH therapy may affect these factors. METHODS: We examined serial cardiac findings for 34 anthracycline-treated childhood cancer survivors with several years of GH therapy and baseline cardiac z scores similar to those of a comparison group (86 similar cancer survivors without GH therapy). RESULTS: LV contractility was decreased among GH-treated patients before, during, and after GH therapy (-1.08 SD below the age-adjusted population mean before therapy and -1.88 SD 4 years after therapy ceased, with each value depressed below normal). Contractility was higher in the control group than in the GH-treated group, with this difference being nearly significant. The GH-treated children had thinner LV walls before GH therapy (-1.38 SD). Wall thickness increased during GH therapy (from -1.38 SD to -1.09 SD after 3 years of GH therapy), but the effect was lost shortly after GH therapy ended and thickness diminished over time (-1.50 SD at 1 year after therapy and -1.96 SD at 4 years). During GH therapy, the wall thickness for the GH-treated group was greater than that for the control group; however, by 4 years after therapy, there was no difference between the GH-treated group and the control group. CONCLUSIONS: GH therapy among anthracycline-treated survivors of childhood cancer increased LV wall thickness, but the effect was lost after therapy was discontinued. The therapy did not affect the progressive LV dysfunction.
Authors: Gregory T Armstrong; Vijaya M Joshi; Liang Zhu; Deokumar Srivastava; Nan Zhang; Kirsten K Ness; Dennis C Stokes; Matthew T Krasin; James A Fowler; Leslie L Robison; Melissa M Hudson; Daniel M Green Journal: J Clin Oncol Date: 2013-01-07 Impact factor: 44.544
Authors: Gregory T Armstrong; Juan Carlos Plana; Nan Zhang; Deokumar Srivastava; Daniel M Green; Kirsten K Ness; F Daniel Donovan; Monika L Metzger; Alejandro Arevalo; Jean-Bernard Durand; Vijaya Joshi; Melissa M Hudson; Leslie L Robison; Scott D Flamm Journal: J Clin Oncol Date: 2012-07-16 Impact factor: 44.544
Authors: Steven E Lipshultz; David C Landy; Gabriela Lopez-Mitnik; Stuart R Lipsitz; Andrea S Hinkle; Louis S Constine; Carol A French; Amy M Rovitelli; Cindy Proukou; M Jacob Adams; Tracie L Miller Journal: J Clin Oncol Date: 2012-03-05 Impact factor: 44.544
Authors: Barry H Trachtenberg; David C Landy; Vivian I Franco; Jacqueline M Henkel; Elliot J Pearson; Tracie L Miller; Steven E Lipshultz Journal: Pediatr Cardiol Date: 2011-01-09 Impact factor: 1.655
Authors: Steven E Lipshultz; Melissa B Diamond; Vivian I Franco; Sanjeev Aggarwal; Kasey Leger; Maria Verônica Santos; Stephen E Sallan; Eric J Chow Journal: Paediatr Drugs Date: 2014-10 Impact factor: 3.022